CD274 and cancer: However, the high CTL dysfunction scores in the IRGPI-low TNBC suggests a compromised cytotoxic response to cancer cells due to immune checkpoints modulated by PD-L1 and PD-1 molecules and thus a potential benefit from ICI therapy for the IRGPI-low patients.